Urotensil-II and the cardiovascular system - The importance of developing modulators

Expert Opinion on Investigational Drugs

Volumn 13, Issue 5, 2004, Pages 479-487

  Doggrell, Sheila A ^a  

^a Doggrell Biomedical Communications   (New Zealand)

Author keywords

Blood vessels; Heart; Urotensin II; Urotensin II receptor agonists; Urotensin II receptor antagonists

Indexed keywords

1 (3 CARBAMIMIDOYLBENZYL) 4 METHYL 1H INDOLE 2 CARBOXYLIC ACID (NAPHTHALEN 1 YLMETHYL)AMIDE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 (4 CHLOROPHENYL) 3 [2 (DIMETHYLAMINO)ETHYL]ISOCHROMAN 1 ONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; AC 7954; BIM 2317; CARDIAC AGENT; DIPHENYLCARBAMIC ACID 4 CARBOXY 2 NITROPHENYL ESTER; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; GALLOPAMIL; INDOMETACIN; MECAMYLAMINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROPEPTIDE RECEPTOR; PARTIAL AGONIST; PHOSPHOLIPASE C INHIBITOR; PRL 2882; PRL 2903; PRL 2915; PROPRANOLOL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RADICICOL; RECEPTOR BLOCKING AGENT; SB 710411; SOMATOSTATIN; THAPSIGARGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II; UROTENSIN;

AORTA CONSTRICTION; ARTERY RESISTANCE; CARDIOVASCULAR SYSTEM; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; HEART DISEASE; HEART FAILURE; HEART PERFUSION; HUMAN; IMMUNOREACTIVITY; LUNG BLOOD VESSEL; MONKEY; MOUSE; NONHUMAN; PROTEIN FUNCTION; RENAL ARTERY; REVIEW; VASOCONSTRICTION; ANIMAL; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HUMANS; INJECTIONS, INTRAVENOUS; UROTENSINS;

EID: 85047692552     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.5.479     Document Type: Review

References (56)

1. Coulouarn Y, Lihrmann I, Jegou S et al.: Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin gene in motorneurons of the spinal cord. Proc. Natl. Acad. Sci. USA (1998) 95:15803-15808.
2. Ames RS, Sarau HM, Chambers JK et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (1999) 401:282-286.
3. Elshourbagy NA, Douglas SA, Shabon U et al.: Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-couple receptors from the mouse and monkey. Br. J. Pharmacol. (2002) 36:9-22.
4. Liu Q, Pong SS, Zeng Z et al.: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. (1999) 266:174-178.
5. Ziltener P, Mueller C, Haenig B, Scherz MW, Nayler O: Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J. Recept. Signal Transduct. Res. (2002) 22:155-168.
6. Mori M, Sugo T, Abe M et al.: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. (1999) 265:123-129.
7. Maguire JJ, Kuc RE, Davenport AP: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol. (2000) 131:441-446.
8. Douglas SA, Sulphizio AC, Piercy V et al.: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, pig, marmoset and cynomolgus monkeys. Br. J. Pharmacol. (2000) 131:1262-1274.
9. Bottrill FE, Douglas SA, Hiley CR, White R: Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol. (2000) 130:1865-1870.
10. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T: Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur. J. Pharmacol. (2000) 402:R5-R7.
11. Gray GA, Jones MR, Sharif I: Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric synthase and cyclooxygenase inhibition. Life Sci. (2001) 69:175-180.
12. Sauzeau V, Le Mellionnec E, Bertoglio J et al.: Human urotensin II-induced contraction and arterial smooth muscle proliferation are mediated by RhoA and Rho-kinase. Circ. Res. (2001) 88:1102-1104.
13. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH: Human urotensin II-induced aorta rings contractions are mediated be protein kinase C, tyrosine kinases and Rho-kinase inhibition by somatostatin receptor antagonists. Eur. J. Pharmacol. (2002) 438:159-170
14. Saetrum Opgaard O, Nothacker E, Ehlert FJ, Krause DN: Human urotensin II mediated vasoconstriction via an increase in inositol phosphates. Eur. J. Pharmacol. (2000) 13:265-271.
15. Watanabe T, Pakala R, Katagiri T, Benedict CR: Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation (2001) 104:16-18.
16. Behm DJ, Harrison SM, Ao Z et al.: Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br. J. Pharmacol. (2003) 139:464-472.
17. MacLean MR, Alexander D, Stirrat A et al.: Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. J. Pharmacol. (2000) 130:201-204.
18. Stirrat A, Gallagher M, Douglas GA et al.: Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. J. Physiol. Heart Circ. Physiol. (2001) 280:H925-H928.
19. Zhang AY, Chen YF, Zhang DX et al.: Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am. J. Physiol. Renal Physiol. (2003) 285:F792-F798.
20. Hillier C, Berry C, Petrie M et al.: Effects of urotensin II in human arteries and veins of varying caliber. Circulation (2001) 103:1378-1381.
21. Paysant J, Rupin A, Simonet S, Fabiani JN, Verbeuren TJ: Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam. Clin. Pharmacol. (2001) 15:227-231.
22. Russell FD, Molenaar P, O'Brien DM: Cardiostimulant effects of urotensin-II in human heart in vitro. Br. J. Pharmacol. (2001) 132:5-9.
23. Tzanidis A, Hannan RD, Thomas WG et al.: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res. (2003) 93:246-253.
24. Zou Y, Nagai R, Yamazaki T: Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. (2001) 508:57-60.
25. Zhu YZ, Wang ZJ, Zhu YC et al.: Urotensin II causes fatal circulatory collapse in anaesthesized cynomolgus monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am. J. Physiol. Heart Circ. Physiol. (2004) 286(3):H830-H836.
26. Affolter JT, Newby DE, Wilkinson IB et al.: No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. J. Clin. Pharmacol. (2002) 54:617-621.
27. Bohm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol. (2002) 135:25-27.
28. Wilkinson IB, Affolter JT, De Haas SL et al.: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res. (2002) 53:341-347.
29. Gibson A, Wallace P, Bern HA: Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen. Comp. Endocrinol. (1986) 64:435-439.
30. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T: Depressor and regionally-selective vasodilator effects of human and urotensin II in conscious rats. Br. J. Pharmacol. (2001) 132:1625-1629.
31. Abdelrahman AM, Pang CC: Involvement of the nitric oxide/L-arinine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci. (2002) 71:819-825.
32. Lu Y, Zhou CJ, Huang DW, Tang CS: Cardiovascular effects of urotensin II in different brain areas. Peptides (2002) 23:1631-1635.
33. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Iida M: Central cardiovascular action of urotensin II in conscious rats. J. Hypertens. (2003) 21:159-165.
34. Watson AM, Lambert GW, Smith KJ, May CN: Urotensin II acts centrally to increase epinephrine and ACTH releases and cause inotropic and chronotropic actions. Hypertension (2003) 42:373-379.
35. Katugampola SD, Kuc RE, Maguire JJ, Davenport AP: G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin. Sci. (2002) 103(Suppl. 48):171S-175S.
36. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A: Congestive heart failure and expression of myocardial urotensin II. Lancet (2002) 359:1990-1997.
37. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG: Plasma urotensin II in heart failure. Lancet (2002) 360:545-546.
38. Russell FD, Meyers D, Galbraith AJ et al.: Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H1576-H1581.
39. Dschietzig T, Bartsch C, Pregla R et al.: Plasma levels and cardiovascular gene expression on urotensin II in human heart failure. Regul. Pept. (2002) 110:33-38.
40. Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG: A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anaesth. Analg. (2003) 97:1501-1503.
41. Matsushita M, Shichiri M, Imai T et al.: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. (2001) 19:2185-2190.
42. Lin Y, Tsuchihashi T, Matsumura K et al.: Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens. Res. (2003) 26:839-845.
43. Heller J, Schepke M, Neef M et al.: Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J. Hepatol. (2002) 37:767-772.
44. Totsune K, Takahashi K, Arihara Z et al.: Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. (2003) 104:1-5.
45. Elshourbagy NA, Douglas SA, Shabon U et al.: Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol. (2002) 136:9-22.
46. Labarrere P, Chatenet C, LePrince J et al.: Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J. Enzyme Inhib. Med. Chem. (2003) 18:77-88.
47. Grieco P, Carotenuto A, Campiglia P et al.: A new, potent urotensin II receptor peptide agonist containing Pen residue in the disulfide bridge. J. Med. Chem. (2002) 45:4391-4394.
48. Camarda V, Guerrini R, Kostenis E et al.: A new ligand for the urotensin II recepror. Br. J. Pharmacol. (2002) 137:311-314.
49. Grieco P, Carotenuto A, Patacchini R et al.: Design, synthesis, conformational analysis, and biological study of urotensin-II lactam analogues. Bioorg. Med. Chem. (2002) 10:3731-3739.
50. Brkovic A, Hattenberger A, Kostenis E et al.: Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J. Pharmacol. Exp. Ther. (2003) 306:1200-1209.
51. Croston GE, Olsson R, Currier EA et al.: Discovery of the first nonpeptide agonist of the GPR14/ urotensin-II receptor: 3-(4-chlorophenyl)-3-(2-dimethylamino)ethyl)isochroman-1-one (AC-7954). J. Med. Chem. (2002) 45:4950-4953.
52. Behm DJ, Herold CL, Ohlstein EH et al.: Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol. (2002) 137:449-458.
53. Herold CL, Behm DJ, Buckley PT et al.: The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. J. Pharmacol. (2003) 139:203-207.
54. Patacchini R, Santicioli P, Giuliani S et al.: Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol. (2003) 140:1155-1158.
55. Flohr S, Kurz M, Kostenis E et al.: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. (2002) 45:1799-1805.
56. Sugo T, Murakami Y, Shimomura Y et al.: Identification of urotensin II-related peptide as the urotensin II immunoreactive molecule in the rat brain. Biochem. Biophys. Res. Commun. (2003) 310:860-868.